# Efficacy and Safety of Tolvaptan in the Treatment of Cardiac-Induced Edema in Patients With Heart Failure

> **NCT01618448** · PHASE3 · COMPLETED · sponsor: **Taiwan Otsuka Pharm. Co., Ltd** · enrollment: 85 (actual)

## Conditions studied

- Cardiac-induced Edema

## Interventions

- **DRUG:** Tolvaptan
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01618448
- **Lead sponsor:** Taiwan Otsuka Pharm. Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-07
- **Primary completion:** 2014-05
- **Final completion:** 2014-12
- **Target enrollment:** 85 (ACTUAL)
- **Last updated:** 2015-06-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01618448

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01618448, "Efficacy and Safety of Tolvaptan in the Treatment of Cardiac-Induced Edema in Patients With Heart Failure". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01618448. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*